ABSTRACT
COVID-19 prematurely ended many lives, particularly among the oldest Americans, but the pandemic also had an indirect effect on health and non-COVID mortality among the working-age population, who suffered the brunt of the economic consequences. This analysis investigates whether monthly excess mortality in the US during 2020 varied by age and cause of death. Based on national-level death counts and population estimates for 1999-2020, negative binomial regression models—fit separately by sex— were used to estimate monthly cause-specific excess mortality by age group during 2020. Among males, 71% non-COVID excess deaths occurred at working ages (25-64), but those ages accounted for only 36% of non-COVID excess deaths in females. The results revealed substantial numbers of excess deaths from external causes (particularly among males), heart disease, diabetes, Alzheimer’s disease (particularly among women), and cerebrovascular disease. For males, the largest share of non-COVID excess deaths resulted from external causes, nearly 80% of which occurred at working ages. Although incorrectly classified COVID-19 deaths may explain some excess non-COVID mortality, misclassification is unlikely to explain the increase in external causes of mortality. Auxiliary analyses suggested that drug-related mortality may be driving the rise in external mortality, but drug overdoses were already increasing for a full year prior to the pandemic. The oldest Americans bore the brunt of COVID-19 mortality, but working-age Americans, particularly men, suffered substantial numbers of excess non-COVID deaths, most commonly from external causes and heart disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by grants from the National Institute of Aging (#1R03-AG058110-01A1 and center grant #P30AG012839) and the Society of Actuaries.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analyses are based on de-identified, secondary data, all of which are publicly available.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
SUMMARY OF MAJOR REVISIONS 1) The main analysis has been updated with the most recent provisional data published by NCHS in early August. 2) The auxiliary analyses (based on crude death rates for sub-categories of external causes) have been updated with the most recent provisional data published by NCHS in early October. 3) Models are now fit separately by sex, which only became possible when data were updated in early August. 4) Additional analyses have been added to explore the sensitivity of estimated excess deaths to the length of time series used to fit the model and the specification of the pre-pandemic time trend. 5) Since it is impossible to know how many deaths would have occurred in 2020 in the absence of a pandemic, the model that best predicts mortality in 2019 is likely to provide the best estimate of expected mortality in 2020. Therefore, the current specification of the pre-pandemic time trend for each outcome has been chosen to maximize predictive accuracy in 2019: linear specification for influenza/pneumonia mortality; quadratic specification for all-cause, heart disease, cerebrovascular disease, Alzheimer's disease, diabetes, and external causes; cubic specification for other respiratory diseases (excluding COVID-19) and cancer.
Data Availability
All of the data used in this analysis are publicly available from the National Center for Health Statistics and the U.S. Census Bureau.
